NASDAQ: OACC
Oaktree Acquisition III Life Sciences Revenue

Oaktree Acquisition III Life Sciences revenue was $0.00 for the trailing 12 months ending Dec 31, 2025, with 150% growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $0.0, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, OACC annual revenue was $0.0, with N/A growth year-over-year.

OACC revenue history

Current Revenue
$0.0
Current Earnings
$7.3M
Current Profit Margin
0%

Be the first to know when OACC announces revenue.

OACC Revenue History By Year

OACC Yearly RevenueOACC RevenueOACC ChangeOACC Revenue Growth
2025-12-31$0.00N/AN/A
2024-12-31$0.00N/AN/A

1 of 1

Oaktree Acquisition III Life Sciences Revenue FAQ

What was OACC's revenue last quarter?

Oaktree Acquisition III Life Sciences (NASDAQ: OACC) reported Q4 2025 revenue of $0.00 up N/A year over year. In the same quarter last year, Oaktree Acquisition III Life Sciences's revenue was $0.00.

What was Oaktree Acquisition III Life Sciences's revenue in 2025?

Oaktree Acquisition III Life Sciences's annual revenue for the twelve months ending Dec 31, 2025 was $0.00, a N/A decrease year over year.

How much does Oaktree Acquisition III Life Sciences make in a day?

Based on Oaktree Acquisition III Life Sciences annual revenue for the past one years, OACC makes an average of $0.00 per day.

What was Oaktree Acquisition III Life Sciences's annual revenue growth in the past year?

As of Q2 2026, Oaktree Acquisition III Life Sciences's revenue has grown null year over year. Oaktree Acquisition III Life Sciences's revenue in the past year totaled $0.00.

How much does Oaktree Acquisition III Life Sciences make in a year?

Oaktree Acquisition III Life Sciences's revenue by year for the past one years is:
  • Oaktree Acquisition III Life Sciences's revenue for the twelve months ending Dec 31, 2025 was $0.00, a N/A decrease year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.